Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 8/20 | 0.51 |
| ▸ | CA1 | P00915 | 8/20 | 0.51 |
| ▸ | CA2 | P00918 | 8/20 | 0.51 |
| ▸ | CA4 | P22748 | 8/20 | 0.51 |
| ▸ | CA9 | Q16790 | 8/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7429470 | 0.88 | LOXL2 (0.50) | CFDCA12CA1CA2CA4 | |
| SCHEMBL19119342 | 0.85 | LOXL2 (0.49) | CFDCA12CA1CA2CA4 | |
| SCHEMBL4035874 | 0.83 | CFD (0.51) | CFDCA12CA1CA2CA9 | |
| SCHEMBL340537 | 0.83 | AKR1C3 (0.55) | CA12CA1CA2CA4CA9 | |
| SCHEMBL5289171 | 0.83 | HPGD (0.54) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3814850 | 0.82 | TPSAB1 (0.46) | LOXL2CYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL7427800 | 0.81 | LOXL2 (0.49) | CFDCA1CA2LOXL2 | |
| SCHEMBL10419779 | 0.80 | NOS3 (0.60) | CA12CA1CA2CA4CA9 | |
| SCHEMBL9181038 | 0.79 | PGK1 (0.46) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3003205 | 0.79 | CFD (0.59) | CFDHTR6LOXL2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | CURACYTE AG (DE) | 2005-06-02 | — | — | US | claimed |
| EP-1483285-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | Curacyte AG (DE) | 2004-12-08 | — | — | EP | claimed |
| WO-2003076457-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | CURACYTE AG (DE) | 2003-09-18 | — | — | WO | claimed |
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | CURACYTE AG (DE) | 2005-06-02 | — | — | US | disclosed |
| EP-1483285-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | Curacyte AG (DE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003076457-A1 | INHIBITORS OF THE BLOOD-CLOTTING FACTOR Xa, PRODUCTION THEREOF AND USE OF THE SAME | CURACYTE AG (DE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119190-A1 | Inhibitors of the blood-clotting factor xa, production thereof and use of the same | SERPINC1, TFPI, F11 | CFD 32/4885CA12 1608/4885CA1 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.